Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M513118200 on January 5, 2006 Originally published In Press as doi:10.1074/jbc.M513118200 on December 23, 2005

J. Biol. Chem., Vol. 281, Issue 10, 6642-6647, March 10, 2006
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
281/10/6642    most recent
M513118200v2
M513118200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lorenzen, I.
Right arrow Articles by Grötzinger, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lorenzen, I.
Right arrow Articles by Grötzinger, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

The Structure of the Interleukin-15{alpha} Receptor and Its Implications for Ligand Binding*

Inken Lorenzen{ddagger}, Andrew J. Dingley§, Yannick Jacques, and Joachim Grötzinger{ddagger}1

From the {ddagger}Biochemisches Institut der Christian-Albrechts-Universität Kiel, Olshausenstrasse 40, 24118 Kiel, Germany, §Department of Biochemistry and Molecular Biology, University College London, Gower Street, London WC1E 6BT, United Kingdom, and INSERM, UMR 601, Groupe de Recherche Cytokines et Récepteurs, Institut de Biologie, Nantes F-44093, France

Received for publication, December 8, 2005


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 
Interleukin (IL)-15 is a member of the small four {alpha}-helix bundle family of cytokines. IL-15 was discovered by its ability to mimic IL-2-mediated T-cell proliferation. Both cytokines share the beta and {gamma} receptor chains of the IL-2 receptor for signal transduction. However, in addition, they target specific {alpha} chain receptors IL-15R{alpha} and IL-2R{alpha}, respectively. The exceptionally high affinity binding of IL-15 to IL-15R{alpha} is mediated by its sushi domain. Here we present the solution structure of the IL-15R{alpha} sushi domain solved by NMR spectroscopy and a model of its complex with IL-15. The model shows that, rather than the familiar hydrophobic forces dominating the interaction interface between cytokines and their cognate receptors, the interaction between the IL-15 and IL-15R{alpha} complex involves a large network of ionic interactions. This type of interaction explains the exceptionally high affinity of the IL-15·IL-15R{alpha} complex, which is essential for the biological effects of this important cytokine and which is not observed in other cytokine/cytokine receptor complexes.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 
Two independent groups recognize that interleukin (IL)2-15 is able to mimic IL-2-mediated T-cell proliferation (1-3). This is due to both cytokines sharing the IL-2 receptor beta (IL-2Rbeta) and the common {gamma} chain receptor for signal transduction (1, 2, 4, 5). The IL-2Rbeta and {gamma} chain receptors are both members of the hematopoietic growth factor receptor superfamily containing the typical cytokine binding module that consists of two fibronectin type III domains. Besides these two receptors, both cytokines each use a specific {alpha} receptor, the IL-15 receptor {alpha} chain (IL-15R{alpha}) and the interleukin-2 receptor {alpha} chain (IL-2R{alpha}) (6). The structure of the quaternary complex between IL-2 and its {alpha}, beta, and {gamma} receptors has very recently been solved by x-ray crystallography (7). Both IL-15R{alpha} and IL-2R{alpha} receptors are highly homologous and exhibit amino acid homology to a group of beta sandwich protein modules called sushi domains. These domains have been described previously in proteins of the complement system and the coagulation cascades (8). Sushi domains have typical sizes of 60-70 residues and contain two cysteine bridges (9, 10). The IL-2R{alpha} consists of two sushi domains, whereas the IL-15R{alpha} contains only one (11). These domains are structurally different from other cytokine receptors, which bind their ligands via cytokine binding modules (12). Both IL-2R{alpha} and IL-15R{alpha} use their sushi domains for ligand binding but with remarkably different affinities. Whereas the IL-2R{alpha} binds IL-2 with low affinity (Ka value of ~108 M-1), the IL-15R{alpha} shows a 1000-fold higher binding affinity to IL-15 (Ka value of ~1011 M-1) (6, 11). IL-2 and IL-15 not only differ in their affinity for their specific {alpha} receptors but also in their tissue distribution. IL-2 is exclusively expressed by activated T-cells, whereas IL-15 has been described to be expressed in nonimmune (keratinocytes, skeletal muscle cells) and immune cells (monocytes and activated T-cells) (6, 11). Although IL-2 and IL-15 share some function, such as T-cell activation, differences in their biological function have been clearly identified by the differences in the phenotypes of knock-out mice. The IL-15 and IL-15R{alpha} knock-out mice show a reduced number of CD8+ memory, natural killer, and natural killer T-cells (13, 14). In contrast, the IL-2 and IL-2R{alpha} knock-out mice exhibit autoimmune phenotypes and an increased number of T- and B-cells (15, 16). Moreover, IL-2 promotes activation-induced cell death, which is suppressed by IL-15 (17). In a number of studies, it has been shown that the latter cytokine is proinflammatory and is associated with the pathogenesis of inflammatory diseases, such as rheumatoid arthritis and psoriasis (18, 19). Because of its broad distribution and high inflammatory potential, the expression of IL-15 is believed to be tightly regulated (20, 21).

Dubois et al. (22) has shown that the sushi domain of IL-15R{alpha} is essential for ligand binding and that eight different splice forms from the IL-15R{alpha} mRNA exist. The splice forms vary by either the presence or absence of exon 2 (which encodes for the sushi domain), exon 3 (which encodes for the linker region), and the alternative use of exon 7 and 7' (which encode the cytoplasmic part of the IL-15R{alpha}). Interestingly, this receptor is not only located at the plasma membrane but also in the nuclear membrane. However, only the splice forms that contain exon 2 have been detected in the nuclear membrane (22). In line with this observation, Nishimura et al. (23) suggest a model of transcriptional regulation mediated via the IL-15 bound to its {alpha} receptor (23).

In addition, it has been shown that a natural form of a soluble IL-15R{alpha} exists. This soluble form is generated by a process called shedding and involves the cleaving of IL-15R{alpha} by a metalloproteinase, namely the tumor necrosis factor-{alpha}-converting enzyme (TACE/ADAM17) (24, 25). The soluble IL-15R{alpha} has been shown to elicit antagonistic properties (24) and thereby prevent collagen-mediated arthritis (26), short term carrageenan-induced inflammation (8), and the induction of allergic inflammation (27). Moreover, in a mouse model, it has been shown to enhance cardiac allograft survival (28). All of these data suggest a promising therapeutic potential for the soluble IL-15R{alpha} receptor.

Many cytokine·cytokine receptor complexes have been analyzed with respect to their interaction mechanisms. Two different modes of interaction between a cytokine and its receptor have been described so far. The growth hormone/growth hormone receptor complex was the first three-dimensional structure of such a complex. Alanine scanning mutagenesis has revealed that the two molecules interact in a "hot spot" manner (29), whereas the IL-4/IL-4R has been described to interact in an "avocado-like" manner (30).

Here we present the three-dimensional structure of IL-15R{alpha} solved by multidimensional NMR spectroscopy. This structure has enabled us to build a model of the IL-15·IL-15R{alpha} complex that reveals a new mode of cytokine/cytokine receptor interaction.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
 REFERENCES
 
Protein Expression, Purification, and Sample Preparation—The mature coding sequence of IL-15R{alpha} was originally cloned in pGEX2T (Amersham Biosciences). This clone was used as a template for amplification of the IL-15R{alpha} sushi domain coding region by PCR. The PCR products were purified, digested using BamHI and HindIII restriction enzymes and ligated into pQE30 (Qiagen). The plasmid was transformed into Escherichia coli SG13009 cells.

Fifty milliliters of minimal medium (6 g of Na2HPO4/liter, 3 g of KH2PO4/liter, 2 g of NaCl/liter, 0.24 g of MgSO4/liter, 2 g of 15NH4Cl/liter, 1.86 g of 13C-glucose or 2 g of 12C-glucose*H2O) containing 50 µg/ml ampicillin and 30 µg/ml kanamycin was inoculated with 500 µl of culture of a single clone and cultured overnight at 37 °C. 350 ml of minimal medium was inoculated with 3.5 ml of the overnight culture and incubated at 37 °C. Expression of the recombinant protein was induced by adding isopropyl-beta-thiogalactopyranoside (final concentration of 1 mM) when the cell culture had reached an OD of ~0.5. The growth of the culture was continued for a further 4 h.

The cells were harvested by centrifugation and resuspended in a lysis buffer (50 mM Tris/HCl, pH 8.0, 1 mM EDTA). Lysis of bacteria was achieved by sonification, and the inclusion bodies were isolated by centrifugation. Inclusion bodies were washed three times with a buffer containing Tween 20 (50 mM Tris/HCl, 1 mM EDTA, 2 mM urea, and 0.5% Tween 20, pH 8.0) and three times with the same buffer containing no detergent. Inclusion bodies were then solubilized in 6 M guanidine hydrochloride, 20 mM sodium phosphate, 20 mM imidazole, 150 mM sodium chloride, and 1 mM dithiothreitol at pH 7.4.

A nickel-nitrilotriacetic acid-agarose column (Qiagen, Hilden, Germany) was equilibrated with the same buffer as before, but instead of 1 mM dithiothreitol, the buffer contained 1 mM reduced glutathione and 0.2 mM oxidized glutathione. The solubilized inclusion bodies were loaded onto the column, and nonspecific protein was removed by washing. The protein was refolded via a gradient of from 6 to 0 M guanidine hydrochloride and then eluted with 250 mM imidazole (36). The imidazole was removed using a NAP column (Amersham Biosciences). The sample was concentrated via an AMICON ultrafiltration cell (Millipore, Eschborn, Germany) to ~1 ml and the buffer exchanged to a buffer containing 7% D2O and 0.03% NaN3. The protein sample was further concentrated to an approximate concentration of 1 mM using VIVA spin 500 concentrators (Vivascience, Hannover, Germany).

NMR Spectroscopy—NMR experiments were recorded at 298 K on Bruker DRX600 and Varian INOVA 600-MHz spectrometers equipped with 5-mm z-gradient 1H/15N/13C probes optimized for 1H detection. Backbone and side chain resonance assignments of the sushi domain of the IL-15R{alpha} were established from a series of three-dimensional triple-resonance experiments (i.e. HNCA, HNCO, (H)C(CO)NH, H(CCO)NH)) and 15N- and 13C-edited total correlation spectroscopy experiments. Distance restraints were obtained from three-dimensional 15N- and 13C-edited nuclear Overhauser effect (NOE) spectroscopy-heteronuclear single quantum correlation experiments, all recorded with a mixing time of 100 ms. A number of hydrogen bond restraints were obtained from a two-dimensional long range HNCO experiment (37) with 13C-{alpha} decoupling during the long 15N-13C' defocusing/refocusing period (38). Proton chemical shifts were referenced to 3-(trimethylsilyl)-propionic acid, whereas 15N and 13C chemical shifts were indirectly referenced (39). All spectra were processed with the NMRPipe program (40) and analyzed with NMRview software (41). The ratio of the intensity of the water and the corresponding 1H/15N diagonal peak (<0.1) in the 15N-edited NOE spectroscopy with water flip-back is an indication of slow amide proton exchange. Therefore, these amide groups are potential proton donors involved in hydrogen bonding.

Structure Calculation—Structure calculations were performed using the Dyana software (42). The structure calculations were based on 1123 NOE distance restraints extracted from the 15N- and 13C-edited NOE spectra. Distances of 1.8 and 5.0 Å were taken as lower and upper limits for all NOE cross-peaks, respectively. In addition, 2 *10 hydrogen bonds, classified by a distance of 1.8-2.4 Å between hydrogen and oxygen and 2.8-3.4 Å between nitrogen and oxygen, were introduced. After preliminary structure calculations, these low resolution structures were searched for potential hydrogen bond acceptors, which then were included in further structural refinement. Distances representing the two disulfide bonds with restraints 2.03-2.15, 3.03-3.13, and 2.97-4.49 Å for SG/SG, SG/CB, and SG/CA distances, respectively, were also included in the final structural refinement calculations. One-hundred structures were initially calculated, of which, 20 structures with the lowest target function were selected. An averaged structure was calculated from the ensemble of the 20 structures and energy-minimized using the steepest descent algorithm implemented in the GROMOS program package (43). The chemical shifts have been deposited in the Biological Magnetic Resonance Bank under accession number 6882, and the coordinates are deposited at the Protein Data Bank under accession code 2ERS.

Model of the IL-15·IL-15R{alpha} Complex—To construct a model of the IL-15·IL-15R{alpha} complex, the recently published structure of the IL-2·IL-2R{alpha} complex was used as a template (31). The IL-15R{alpha} was superimposed with the IL-2R{alpha}, and our recently published model of the IL-15 (32) was superimposed onto the IL-2 structure. The program WHATIF (44) was used to calculate the solvent accessibilities of the bound as well as the free proteins. For graphical representations, the programs RIBBONS (45) and GRASP (46) were used.


   RESULTS AND DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
REFERENCES
 
Structure of IL-15R{alpha}—The two-dimensional 1H-15N heteronuclear single quantum correlation spectrum exhibits well resolved resonances. Sequential assignment information was obtained from the three-dimensional experiments and includes the three asparagine side chain amide-proton pairs (Fig. 1). The absence of the 1H-15N amide frequencies for Gly-68 and Ser-71 is presumably because of chemical exchange at pH 7.4. The 12-residue N-terminal His tag is missing in all 15N-edited spectra and was therefore not included in the structure calculations. Residue Ile-31 represents the first residue of the mature protein domain. The aliphatic side chains of Gly-68 and Ser-71 and Pro-34-36 and 89 were assigned using the 13C-edited spectra.

Fig. 2A shows the average structure of the sushi domain of the IL-15R{alpha}. The protein contains five beta-strands, which comprise residues 52-56 (strand C), 64-65 (strand C'), 72-77 (strand D), 84-86 (strand E), and 93-94 (strand E'). The sushi domain of IL-15R{alpha} exhibits the canonical fold of a sushi domain, a central beta-sheet built from strands C, D, and E. However, compared with other sushi domains, strands A and B are absent. The ability of the first loop (loop A) to form a beta-strand is impaired by the presence of three consecutive proline residues (Pro-34-Pro-36). Consequently, the typical 2-on-3 beta-sandwich cannot be formed. The strands C' and E' form an additional short beta-sheet. The disulfide bridge between Cys-33 and Cys-75 connect the N terminus with strand D, whereas the second disulfide bond between Cys-59 and Cys-93 connects loop 2 with strand E'.


Figure 1
View larger version (25K):
[in this window]
[in a new window]
  		FIGURE 1.
1H-15N heteronuclear single quantum correlation spectrum of the sushi domain of the IL-15R{alpha}. The spectrum was acquired at 25 °C, and the resonance assignments are indicated. Because of the low intensity of the cross-peaks, residues Cys-59, Gly-62, Ala-67, and Lys-79 are not visible, andtheir locations are marked with a circle.

 


Figure 2
View larger version (43K):
[in this window]
[in a new window]
  		FIGURE 2.
The structure of the sushi domain of the IL-15R{alpha}. A, ribbon representation of the average energy-minimized structure. The two disulfide bonds are yellow, and the N and C termini are labeled. B, stereo view of 20 superimposed structures in spaghetti representation and generated by distance geometry calculations, N and C denotes the N and C termini, respectively.

 
The ensemble of 20 superimposed structures is depicted in Fig. 2B and displays an overall root mean square deviation of 1.48 ± 0.29 for the backbone, whereas the secondary structure elements exhibit a root mean square deviation of 0.82 ± 0.20 (Table 1). Interestingly, large regions of the domain exhibit no regular secondary structure elements. Only ~29% of the residues are involved in the assembly of the five beta-strands. The residues Val-39, Glu-40 (loop A), and Thr-87 (loop E) display backbone dihedral angles in the disallowed areas of a Ramachandran plot (data not shown) and are located in the less structured parts of the molecule.


View this table:
[in this window]
[in a new window]
  		TABLE 1
Structural statistic for the 20 conformers

No distance restraints were violated by >0.5 Å for any of the structures.

 
Comparison with IL-2R{alpha}—The structure of the IL-2R{alpha} in complex with its ligand has been solved by x-ray crystallography (31). As such, the solution structure of the IL-15R{alpha} with the IL-2R{alpha} structure were superimposed in an effort to gain insight into any significant structural differences. Because IL-2R{alpha} contains two sushi domains but ligand binding is mediated primarily by the N-terminal domain (IL-2R{alpha}-D1), the superimposition was performed using this domain. As shown in Fig. 3, the central regions of both sushi domains appear rather similar. The strands C, C', D, and E' in the sushi domain of IL-15R{alpha} are in the same position as the corresponding beta-strands C*, C'*, D*, and E'* of IL-2R{alpha}-D1. Whereas the E*-loop of the IL-2R{alpha}-D1 domain is not resolved in the x-ray structure, the structure of the IL-15R{alpha} exhibits a fourth beta-strand in this region.

The two domains of the IL-2R{alpha} show a beta-strand exchange. Loop A* and beta-strand B* are part of D2, whereas loop F* and strand G* are part of D1. In the structure of the IL-15R{alpha} sushi domain, loop F* of IL-2R{alpha} corresponds to loop A. Because of this beta-strand exchange between the domains, the orientation of beta-strand G* in the IL-2R{alpha} is different from the corresponding loop B in the IL-15R{alpha}. The beta-strand G* of the IL-2R{alpha} is part of the beta-sheet consisting of the three strands D*, C*, and G*, whereas loop B of IL-15R{alpha} lies behind strand C and runs perpendicular to loop A. This rearrangement has notable implications for ligand binding between the two receptors.

Model of the IL-15·IL-15R{alpha} Complex—With the help of the experimentally derived structure of the IL-15R{alpha} sushi domain and the previously published model of IL-15 (32), a model of the IL-15·IL-15R{alpha} complex was built. To orient the two molecules relative to each other, the recently published structure of the IL-2·IL-2R{alpha} complex was used as a template (31). The three-dimensional model of the IL-15·IL-15R{alpha} complex is shown in Fig. 4A. In this complex, the sushi domain is located on top of IL-15 and utilizes the C-, C'-, and D-strands to form the interface for ligand interaction. The binding epitope of IL-15 consists of the AB-loop, the B-helix, and regions of the CD-loop.

The AB-loop (amino acid residues 23-33) of IL-15 has been proposed to be involved in binding to high affinity IL-15R{alpha} (33). On the basis of peptide scanning experiments and site-directed mutagenesis studies, Bernard et al. (32) suggests the B- and C-helices of IL-15 are involved in receptor binding. Whereas the participation of the AB-loop and the B-helix could be confirmed by this model of the IL-15·IL-15R{alpha} complex, the interaction of helix C of IL-15 with the sushi domain do not fit the model because of the limited size of the sushi domain and the location of the C-helix not proximal to the binding interface.


Figure 3
View larger version (27K):
[in this window]
[in a new window]
  		FIGURE 3.
The superimposition of the sushi domains of IL-15R{alpha} and IL-2R{alpha}. The IL-15R{alpha} (blue) was superimposed with the D1 of IL-2R{alpha} (green). The labeling of the IL-2R{alpha} domain is marked with an asterisk.

 
Fig. 4B shows a close-up of the IL-15/IL-15R{alpha} binding interface. Most of the residues participating in the interaction are charged residues. Here, the binding epitope of the IL-15R{alpha} sushi domain exhibits almost exclusively basic residues, whereas the IL-15 epitope comprises acidic residues. Two arginines (Arg-54 and Arg-56) and two lysines (Lys-64 and Lys-66) from the IL-15R{alpha} and two aspartic acids (Asp-30 and Asp-56) and four glutamic acids (Glu-53, Glu-87, Glu-89, and Glu-93) from IL-15 form a large surface network of charge/charge interactions, rather than specific ion pairs. In contrast to other cytokine·cytokine receptor complexes, only a few hydrophobic residues (Leu-72 and Ala-67 of the sushi domain and Leu-52 and Leu-45 from IL-15) (see Fig. 4B) are located at the binding interface. In addition, these hydrophobic residues are located at the edges of the binding surface and are, at least partially, accessible by surrounding water molecules. Exchange of two hydrophobic residues Leu-52 and Leu-45 in IL-15 to aspartic acid residues leads to mutants with an increased affinity for IL-15R{alpha} and greater proliferation potential (32). The IL-15·IL-15R{alpha} model supports this observation, as the complex reveals that the introduction of additional negative charges, which are located in close vicinity to the network of interacting charges, (see Fig. 4B) leads to an extension of the negatively charged surface area of IL-15 and thereby a potential increase in the stability of the complex.


Figure 4
View larger version (27K):
[in this window]
[in a new window]
  		FIGURE 4.
Model of the IL-15 with its {alpha} receptor sushi domain as ribbon representation. A, model of the complex of the sushi domain (blue) and an IL-15 model (yellow). B, the proposed binding interface between IL-15 and IL-15R{alpha}.

 
Comparison between the IL-15·IL-15R{alpha} and the IL-2·IL-2R{alpha} Complexes—The kinetic binding constants (kon and koff) and affinities (KD) of IL-15 and IL-2 to their respective {alpha} receptors have been reported (Table 2). The KD of IL-15 is three orders of magnitude higher compared with that of IL-2. To examine the potential structural origin for this difference in affinities, we analyzed and compared the interaction areas of the complexes by calculating the changes in the accessible surface areas upon complex formation (Fig. 5A). Both cytokines IL-15 and IL-2 utilize residues located in almost identical structural regions, namely the AB-loop, the B-helix, and the CD-loop. In contrast, a remarkable difference is clearly observable between the two {alpha} receptors. Although in both receptors, residues involved in the interaction with the ligand are located in the E-loop and D- and C-strands, the interaction of IL-2 with IL-2R{alpha} also involves residues located in the G*-strand. Because of the absence of strand exchange, the corresponding region in the IL-15R{alpha} (B-loop) is not involved in the formation of the complex (see Fig. 3). The absence of the participation of the B-loop in the interaction is apparently because of the partial masking of this structural element behind the C-strand (Fig. 4A). Consequently, the interaction area is larger for the IL-2·IL-2R{alpha} complex, yet the experimentally derived binding constant is a thousand-fold lower compared with the IL-15/IL-15R{alpha} complex. This discrepancy must be explained by the different nature of the interaction between the respective cytokines and their receptors. The interaction area of the IL-2·IL-2R{alpha} complex has been described to consist of a hydrophobic core region, surrounded by hydrophilic residues that shield this hydrophobic patch from water molecules. This mode of interaction has been observed in many cytokine·cytokine receptor complexes, such as the growth hormone·growth hormone receptor and the IL-6·IL-6R{alpha} complex (29, 34, 35). In contrast, the IL-15/IL-15R{alpha} interaction area consists almost exclusively of charged residues. This remarkable difference between the IL-15·IL-5R{alpha} and IL-2·IL-2R{alpha} complexes is also reflected by the calculated electrostatic surface potentials of the involved molecules (see Fig. 5B). The highly positive charged surface of the sushi domain of the IL-15R{alpha} fits nicely against the highly negative charged IL-15 binding region. It is evident, that the interaction between IL-2 and IL-2R{alpha} involves a much lower number of charged residues. Comparing the kinetic constants of complex formation (kon, koff) of IL-15·IL-5R{alpha} and IL-2·IL-2R{alpha}, the most striking difference is observed in the koff rate constants, which differ by about five orders of magnitude. The kinetic constant koff is the probability that a complex will dissociate and is therefore a direct measure of the heights of the activation barrier between the complex and the free molecules. A complex such as IL-15·IL-15R, with such a low koff value is kinetically trapped. This is a typical phenomenon of a polyanion·polycation complex. With respect to this, the IL-15/IL-15R{alpha} complex resembles such a polyanion/polycation interaction, which is responsible for the high affinity of IL-15 to the IL-15R{alpha} receptor.


View this table:
[in this window]
[in a new window]
  		TABLE 2
Binding constants of cytokines to their cognate receptors

 


Figure 5
View larger version (34K):
[in this window]
[in a new window]
  		FIGURE 5.
Comparison of the IL-15·IL-15R{alpha} and IL-2·IL-2R{alpha} complexes. A, change in the solvent accessibility of the receptors and ligands upon complex formation. The solvent accessibility of the side chains of IL-15, IL-15R{alpha}, IL-2, and IL-2R{alpha} in the free and bound states was calculated with the program WHATIF (44), and the change for each protein was plotted. The homologous structural regions are labeled and marked with black bars. B, electrostatic surface potential of the sushi domains of IL-15R{alpha} and IL-2, as well as of their cytokines. The complex of the {alpha} receptors and their ligands were rotated by 90° (the receptors, left hand; the ligands, right hand). Where the binding site potential is displayed, negatively charged is pictured in red, and positively charged is pictured in blue.

 
Specific antibodies against the IL-2Rbeta chain are already used in clinical trials to inhibit signaling of both cytokines IL-2 and IL-15 (18), but the soluble IL-15R{alpha} serves as a potential specific antagonist for IL-15 signaling (24). Because the presented IL-15·IL-15R{alpha} complex is in good agreement with data from site-directed mutagenesis data and the results might therefore serve as a basis for the rational design of more potent IL-15 antagonists, such antagonists can be of valuable therapeutic interest for the treatment of inflammatory diseases.


   FOOTNOTES
 
The atomic coordinates and structure factors (code 2ERS) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).

* This work was supported by a grant of the Deutsche Forschungsgemeinschaft (SFB 415). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

1 To whom correspondence should be addressed: Biochemisches Institut, Christian-Albrechts-Universität Kiel, Olshausenstr. 40, D-24118 Kiel, Germany. Tel.: 49-431-8801686; Fax: 49-431-8805007; E-mail: jgroetzinger{at}biochem.uni-kiel.de.

2 The abbreviations used are: IL, interleukin; IL-2R, interleukin-2 receptor; NOE, nuclear Overhauser effect. Back


   ACKNOWLEDGMENTS
 
We thank Sonja Hollmer and Heiko Kässner (Forschungszentrum Borstel) for excellent technical assistance.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 

  1. Grabstein, K. H., Eisenman, J., Shanebeck, K., Rauch, C., Srinivasan, S., Fung, V., Beers, C., Richardson, J., Schoenborn, M. A., Ahdieh, M., Johnson, L., Alderson, M. R., Watson, J. D., Anderson, D. M., and Giri, J. G. (1994) Science 264, 965-968[Abstract/Free Full Text]
  2. Bamford, R. N., Grant, A. J., Burton, J. D., Peters, C., Kurys, G., Goldman, C. K., Brennan, J., Roessler, E., and Waldmann, T. A. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 4940-4944[Abstract/Free Full Text]
  3. Burton, J. D., Bamford, R. N., Peters, C., Grant, A. J., Kurys, G., Goldman, C. K., Brennan, J., Roessler, E., and Waldmann, T. A. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 4935-4939[Abstract/Free Full Text]
  4. Giri, J. G., Ahdieh, M., Eisenman, J., Shanebeck, K., Grabstein, K., Kumaki, S., Namen, A., Park, L. S., Cosman, D., and Anderson, D. (1994) EMBO J. 13, 2822-2830[Medline] [Order article via Infotrieve]
  5. Carson, W. E., Giri, J. G., Lindemann, M. J., Linett, M. L., Ahdieh, M., Paxton, R., Anderson, D., Eisenmann, J., Grabstein, K., and Caligiuri, M. A. (1994) J. Exp. Med. 180, 1395-1403[Abstract/Free Full Text]
  6. Giri, J. G., Kumaki, S., Ahdieh, M., Friend, D. J., Loomis, A., Shanebeck, K., DuBose, R., Cosman, D., Park, L. S., and Anderson, D. M. (1995) EMBO J. 14, 3654-3663[Medline] [Order article via Infotrieve]
  7. Wang, X., Rickert, M., and Garcia, K. C. (2005) Science 310, 1159-1163[Abstract/Free Full Text]
  8. Wei, X., Orchardson, M., Gracie, J. A., Leung, B. P., Gao, B., Guan, H., Niedbala, W., Paterson, G. K., McInnes, I. B., and Liew, F. Y. (2001) J. Immunol. 167, 277-282[Abstract/Free Full Text]
  9. Perkins, S. J., Haris, P. I., Sim, R. B., and Chapman, D. (1988) Biochemistry 27, 4004-4012[CrossRef][Medline] [Order article via Infotrieve]
  10. Norman, D. G., Barlow, P. N., Baron, M., Day, A. J., Sim, R. B., and Campbell, I. D. (1991) J. Mol. Biol. 219, 717-725[CrossRef][Medline] [Order article via Infotrieve]
  11. Anderson, D. M., Kumaki, S., Ahdieh, M., Bertles, J., Tometsko, M., Loomis, A., Giri, J., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., Valentine, V., Shapiro, D. N., Morris, S. W., Park, L. S., and Cosman, D. (1995) J. Biol. Chem. 270, 29862-29869[Abstract/Free Full Text]
  12. Grötzinger, J. (2002) Biochim. Biophys. Acta 1592, 215-223[Medline] [Order article via Infotrieve]
  13. Kennedy, M. K., Glaccum, M., Brown, S. N., Butz, E. A., Viney, J. L., Embers, M., Matsuki, N., Charrier, K., Sedger, L., Willis, C. R., Brasel, K., Morrissey, P. J., Stocking, K., Schuh, J. C., Joyce, S., and Peschon, J. J. (2000) J. Exp. Med. 191, 771-780[Abstract/Free Full Text]
  14. Lodolce, J. P., Boone, D. L., Chai, S., Swain, R. E., Dassopoulos, T., Trettin, S., and Ma, A. (1998) Immunity 9, 669-676[CrossRef][Medline] [Order article via Infotrieve]
  15. Kundig, T. M., Schorle, H., Bachmann, M. F., Hengartner, H., Zinkernagel, R. M., and Horak, I. (1993) Science 262, 1059-1061[Abstract/Free Full Text]
  16. Willerford, D. M., Chen, J., Ferry, J. A., Davidson, L., Ma, A., and Alt, F. W. (1995) Immunity 3, 521-530[CrossRef][Medline] [Order article via Infotrieve]
  17. Marks-Konczalik, J., Dubois, S., Losi, J. M., Sabzevari, H., Yamada, N., Feigenbaum, L., Waldmann, T. A., and Tagaya, Y. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 11445-11450[Abstract/Free Full Text]
  18. Waldmann, T. A. (2004) Arthritis Res. Ther. 6, 174-177[CrossRef][Medline] [Order article via Infotrieve]
  19. McInnes, I. B., and Gracie, J. A. (2004) Curr. Opin. Pharmacol. 4, 392-397[CrossRef][Medline] [Order article via Infotrieve]
  20. Fehniger, T. A., and Caligiuri, M. A. (2001) Blood 97, 14-32[Free Full Text]
  21. Waldmann, T. A., and Tagaya, Y. (1999) Annu. Rev. Immunol. 17, 19-49[CrossRef][Medline] [Order article via Infotrieve]
  22. Dubois, S., Magrangeas, F., Lehours, P., Raher, S., Bernard, J., Boisteau, O., Leroy, S., Minvielle, S., Godard, A., and Jacques, Y. (1999) J. Biol. Chem. 274, 26978-26984[Abstract/Free Full Text]
  23. Nishimura, H., Fujimoto, A., Tamura, N., Yajima, T., Wajjwalku, W., and Yoshikai, Y. (2005) FASEB J. 19, 19-28[Abstract/Free Full Text]
  24. Mortier, E., Bernard, J., Plet, A., and Jacques, Y. (2004) J. Immunol. 173, 1681-1688[Abstract/Free Full Text]
  25. Budagian, V., Bulanova, E., Orinska, Z., Ludwig, A., Rose-John, S., Saftig, P., Borden, E. C., and Bulfone-Paus, S. (2004) J. Biol. Chem. 279, 40368-40375[Abstract/Free Full Text]
  26. Ruchatz, H., Leung, B. P., Wei, X. Q., McInnes, I. B., and Liew, F. Y. (1998) J. Immunol. 160, 5654-5660[Abstract/Free Full Text]
  27. Rückert, R., Brandt, K., Braun, A., Hoymann, H. G., Herz, U., Budagian, V., Durkop, H., Renz, H., and Bulfone-Paus, S. (2005) J. Immunol. 174, 5507-5515[Abstract/Free Full Text]
  28. Smith, X. G., Bolton, E. M., Ruchatz, H., Wei, X., Liew, F. Y., and Bradley, J. A. (2000) J. Immunol. 165, 3444-3450[Abstract/Free Full Text]
  29. Clackson, T., and Wells, J. A. (1995) Science 267, 383-386[Abstract/Free Full Text]
  30. Hage, T., Sebald, W., and Reinemer, P. (1999) Cell 97, 271-281[CrossRef][Medline] [Order article via Infotrieve]
  31. Rickert, M., Wang, X., Boulanger, M. J., Goriatcheva, N., and Garcia, K. C. (2005) Science 308, 1477-1480[Abstract/Free Full Text]
  32. Bernard, J., Harb, C., Mortier, E., Quemener, A., Meloen, R. H., Vermot-Desroches, C., Wijdeness, J., van Dijken, P., Grötzinger, J., Slootstra, J. W., Plet, A., and Jacques, Y. (2004) J. Biol. Chem. 279, 24313-24322[Abstract/Free Full Text]
  33. Pettit, D. K., Bonnert, T. P., Eisenman, J., Srinivasan, S., Paxton, R., Beers, C., Lynch, D., Miller, B., Yost, J., Grabstein, K. H., and Gombotz, W. R. (1997) J. Biol. Chem. 272, 2312-2318[Abstract/Free Full Text]
  34. Boulanger, M. J., Chow, D.-C. Brevnova, E. E., and Garcia, K. C. (2003) Science 300, 2101-2104[Abstract/Free Full Text]
  35. Wells, J. A. (1996) Annu. Rev. Biochem. 65, 609-634[CrossRef][Medline] [Order article via Infotrieve]
  36. Matsumoto, M., Misawa, S., Tsumoto, K., Kumagai, I., Hayashi, H., and Kobayashi, Y. (2003) Protein Expression Purif. 31, 64-71[CrossRef][Medline] [Order article via Infotrieve]
  37. Cordier, F., and Grzesiek, S. (1999) J. Am. Chem. Soc. 121, 1601-1602[CrossRef]
  38. Liu, A., Hu, W., Majumdar, A., Rosen, M. K., and Patel, D. J. (2000) J. Biomol. NMR 17, 79-82[CrossRef][Medline] [Order article via Infotrieve]
  39. Markley, J. L., Bax, A., Arata, Y., Hilbers, C. W., Kaptein, R., Sykes, B. D., Wright, P. E., and Wuthrich, K. (1998) J. Biomol. NMR 12, 1-23[CrossRef][Medline] [Order article via Infotrieve]
  40. Delagio, F., Grzesiek, S., Vuister, G. W., Zhu, G., Pfeifer, J., and Bax, A. (1995) J. Biomol. NMR 6, 277-293[Medline] [Order article via Infotrieve]
  41. Johnson, B. A., and Blevins, R. A. (1994) J. Biomol. NMR 4, 603-614[CrossRef]
  42. Güntert, P., Mumenthaler, C., and Wüthrich, K. (1997) J. Mol. Biol. 273, 283-298[CrossRef][Medline] [Order article via Infotrieve]
  43. van Gunsteren, W. F., Billeter, S. R., Eising, A. A., Hünenberger, P. H., Krüger, P., Mark, A. E., Scott, W. R. P., and Tironi, I. G. (1996) Biomolecular Simulation: The GROMOS96 Manual and User Guide, vdf Hochschulverlag AG, Zürich, Switzerland
  44. Vriend, G. (1990) J. Mol. Graph. 8, 52-56[CrossRef][Medline] [Order article via Infotrieve]
  45. Carson, M. (1991) J. Appl. Crystallogr. 24, 946-950[CrossRef]
  46. Nicholls, A., Sharp, K. A., and Honig, B. (1991) Proteins 11, 281-296[CrossRef][Medline] [Order article via Infotrieve]
  47. Liparoto, S. F., Myszka, D. G., Wu, Z., Goldstein, B., Laue, T. M., and Ciardelli, T. L. (2002) Biochemistry 41, 2543-2551[CrossRef][Medline] [Order article via Infotrieve]
  48. Shen, B. J., Hage, T., and Sebald, W. (1996) Eur. J. Biochem. 240, 252-261[Medline] [Order article via Infotrieve]
  49. Weiergräber, O., Hemmann, U., Küster, A., Müller-Newen, G., Schneider, J., Rose-John, S., Kurschat, P., Brakenhoff, J. P., Hart, M. H., Stabel, S., and Heinrich, P. C. (1995) Eur. J. Biochem. 234, 661-669[Medline] [Order article via Infotrieve]
  50. Mortier, E., Quemener, A., Vusio, P., Lorenzen, I., Boublik, Y., Grötzinger, J., Plet, A., and Jacques, Y. (2006) J. Biol. Chem. 281, 1612-1619[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
H. P. Carroll, V. Paunovic, and M. Gadina
Signalling, inflammation and arthritis: Crossed signals: the role of interleukin-15 and -18 in autoimmunity
Rheumatology, September 1, 2008; 47(9): 1269 - 1277.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
E. H. Duitman, Z. Orinska, E. Bulanova, R. Paus, and S. Bulfone-Paus
How a Cytokine Is Chaperoned through the Secretory Pathway by Complexing with Its Own Receptor: Lessons from Interleukin-15 (IL-15)/IL-15 Receptor {alpha}
Mol. Cell. Biol., August 1, 2008; 28(15): 4851 - 4861.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. K. Olsen, N. Ota, S. Kishishita, M. Kukimoto-Niino, K. Murayama, H. Uchiyama, M. Toyama, T. Terada, M. Shirouzu, O. Kanagawa, et al.
Crystal Structure of the Interleukin-15{middle dot}Interleukin-15 Receptor {alpha} Complex: INSIGHTS INTO TRANS AND CIS PRESENTATION
J. Biol. Chem., December 21, 2007; 282(51): 37191 - 37204.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Rafei, J. H. Wu, B. Annabi, L. Lejeune, M. Francois, and J. Galipeau
A GMCSF and IL-15 fusokine leads to paradoxical immunosuppression in vivo via asymmetrical JAK/STAT signaling through the IL-15 receptor complex
Blood, March 1, 2007; 109(5): 2234 - 2242.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. P. Rubinstein, M. Kovar, J. F. Purton, J.-H. Cho, O. Boyman, C. D. Surh, and J. Sprent
Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}
PNAS, June 13, 2006; 103(24): 9166 - 9171.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
281/10/6642    most recent
M513118200v2
M513118200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lorenzen, I.
Right arrow Articles by Grötzinger, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lorenzen, I.
Right arrow Articles by Grötzinger, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement